Abiopharma

Fishman Peter L. 🟡 adjusted position in 3.5K shares (1 derivative) of AMARIN CORP PLC\UK (AMRN) at $13.96 Transaction Date: Jan 02, 2026 | Filing ID: 004724

Keenan David Paul 🟡 adjusted position in 5.5K shares (1 derivative) of AMARIN CORP PLC\UK (AMRN) at $13.96 Transaction Date: Jan 02, 2026 | Filing ID: 004722

Provoost Jonathan 🟡 adjusted position in 5.9K shares (1 derivative) of AMARIN CORP PLC\UK (AMRN) at $13.96 Transaction Date: Jan 02, 2026 | Filing ID: 004719

Ketchum Steven B 🟡 adjusted position in 5.3K shares (1 derivative) of AMARIN CORP PLC\UK (AMRN) at $13.96 Transaction Date: Jan 02, 2026 | Filing ID: 004718

GE HealthCare Recommends Shareholders Reject “Mini-Tender” Offer by Potemkin Limited

Aptar Digital Health and ŌURA Collaborate to Advance Migraine Insights by Connecting Migraine Buddy® with Oura Ring

📋 Meisner Derek M (Officer) plans to sell 11K shares of Acumen Pharmaceuticals, Inc. (at $1.97 each, total $21K) Filed: Jan 06, 2026 | ID: 000015

📋 MPM Asset Management LLC (Shareholder) plans to sell 31K shares of Werewolf Therapeutics, Inc. (at $0.64 each, total $20K) Filed: Jan 06, 2026 | ID: 000958

(99% Neutral) Cibus, Inc. (CBUS) Announces Business Combination

📋 MPM Asset Management Investors BV2014 LLC (Shareholder) plans to sell 7K shares of Werewolf Therapeutics, Inc. (at $0.64 each, total $4K) Filed: Jan 06, 2026 | ID: 000956

📋 MPM BioVentures 2014 (B), L.P. (Shareholder) plans to sell 13K shares of Werewolf Therapeutics, Inc. (at $0.64 each, total $9K) Filed: Jan 06, 2026 | ID: 000954

📋 UBS Oncology Impact Fund, L.P. (Shareholder) plans to sell 164K shares of Werewolf Therapeutics, Inc. (at $0.64 each, total $106K) Filed: Jan 06, 2026 | ID: 000951

Director Solomon Darlene J. S. 🟡 adjusted position in 1.8K shares (2 derivative) of NOVANTA INC (NOVT) Transaction Date: Jan 02, 2026 | Filing ID: 000016

Director Hege Kristen 🔴 sold 14.7K shares (17 derivative) of Mersana Therapeutics, Inc. (MRSN) at $572.50 ($1.8M) Transaction Date: Jan 06, 2026 | Filing ID: 001389

Director SHALLCROSS STEVEN A 🟢 acquired 475.0K shares (1 derivative) of Theriva Biologics, Inc. (TOVX) at $0.24 Transaction Date: Jan 05, 2026 | Filing ID: 001388